Scisparc Ltd 最大收入来源是 Drug Development,在最近的收益报告中收入为 2,879,000。就地区而言, Israel 是 Scisparc Ltd 的主要市场,收入为 2,879,000。
Scisparc Ltd 是否盈利?
不,根据最新的财务报表,Scisparc Ltd 的净损失为 $0
Scisparc Ltd 有负债吗?
不,Scisparc Ltd 的负债为 0
Scisparc Ltd 的流通股有多少?
Scisparc Ltd 的总流通股为 0
关键数据
前收盘价
$4.55
开盘价
$4.31
当日区间
$4 - $4.49
52周范围
$2.98 - $80.1
交易量
8.0K
平均成交量
345.6K
股息收益率
--
每股收益(TTM)
-1.51
市值
$2.4M
什么是 SPRC?
SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.